Replication of Respiratory Syncytial Virus Is Inhibited by the Host Defense Molecule Viperin

Journal of Innate Immunity - Tập 5 Số 1 - Trang 60-71 - 2013
Glen McGillivary1, Zachary Jordan, Mark E. Peeples2, Lauren O. Bakaletz2
1Center for Microbial Pathogenesis, The Research Institute, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio 43205-2696, USA.
2College of Medicine

Tóm tắt

Respiratory syncytial virus (RSV) is an important viral pathogen of otitis media, bronchiolitis, and pneumonia. As infection of the upper airways is a precondition for the development of these diseases, understanding RSV pathogenesis and the host response induced by RSV in this niche may enable the development of novel therapeutic strategies against this virus. We have used a microarray approach and showed that expression of the gene that encodes the antiviral protein viperin was significantly upregulated in the chinchilla nasopharynx up to 1 week after RSV challenge. Overexpression of human viperin in vitro diminished the ability of RSV to infect HeLa or A549 cells. Furthermore, transduction of the chinchilla airways with a recombinant adeno-associated virus vector that encodes <i>viperin</i> resulted in reduced titers of RSV in the nasopharyngeal lavage fluid. Collectively, these data indicated that viperin plays a significant role in the innate immune defense against RSV.

Từ khóa


Tài liệu tham khảo

10.1056%2FNEJM200106213442507

10.1016%2FS0140-6736%2810%2960206-1

10.1007%2Fs007050050156

10.1128%2FJVI.74.22.10508-10513.2000

10.1038%2Fnm.2444

10.1128%2FJVI.01813-10

10.1016%2Fj.virol.2007.08.007

10.1128%2FJVI.74.18.8234-8242.2000

10.1186%2F1743-422X-5-116

10.1128%2FJVI.78.8.4363-4369.2004

10.1128%2FJVI.76.11.5654-5666.2002

10.1038%2F80833

10.1074%2Fjbc.M308093200

10.1128%2FJVI.01740-06

10.1038%2Fnri888

10.1128%2FJVI.02220-06

10.1073%2Fpnas.011593298

10.1089%2Fjir.2010.0127

10.1002%2Fhep.20844

10.1016%2Fj.chom.2007.06.009

10.1128%2FJVI.02113-07

10.1128%2FJVI.02199-09

10.1128%2FJVI.01282-07

10.1128%2FJVI.00438-08

10.1164%2Frccm.200805-670OC

10.1111%2Fj.1462-5822.2009.01339.x

10.1016%2Fj.molimm.2006.10.008

10.1128%2FJVI.79.10.6035-6042.2005

10.1371%2Fjournal.pone.0013224

10.1128%2FJVI.75.15.6825-6834.2001

10.1001%2Farchoto.2008.513

10.1128%2FJVI.00302-10

10.1016%2FS0042-6822%2803%2900288-5

10.1172%2FJCI57367

10.1073%2Fpnas.97.7.3428

10.1016%2Fj.vaccine.2006.10.045

10.1182%2Fblood-2007-01-071340

10.1371%2Fjournal.pone.0021461

10.1074%2Fjbc.M101559200

10.1128%2FJVI.00895-06

10.4049%2Fjimmunol.0903752

10.1136%2Fadc.71.5.428

10.1086%2F428589

10.1093%2Finfdis%2Fjir280

10.1016%2Fj.chom.2009.07.006